Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
In patients with resectable NSCLC, neoadjuvant nivolumab plus chemotherapy resulted in significantly longer event-free survival and a higher percentage of patients with a pathol...
Publications
2 shownFive-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study
PURPOSE Pembrolizumab monotherapy has demonstrated durable antitumor activity in advanced programmed death ligand 1 (PD-L1)–expressing non‒small-cell lung cancer (NSCLC). We rep...
Frequent Co-Authors
Researcher Info
- h-index
- 2
- Publications
- 2
- Citations
- 3,272
- Institution
- Shanghai Cancer Institute
External Links
Identifiers
- ORCID
- 0000-0002-7620-0098
Impact Metrics
h-index
2
h-index: Number of publications with at least h citations each.